Expression of miR-520d in breast cancer
-
Shahram Savad
,
Parvin Mahdipour
,
Hoda Shirdast
,
Ladan Nekoohesh
,
Leili Nekoohesh
,
Reza Shirkoohi
,
Vahid Nikooee
,
Mohammad Miryounesi
,
Mohammad Hasan Modarresi
Abstract
Background: Breast cancer is the most common cancer in women. Non-coding RNAsespecially miRNAs have important regulatory roles in cancer. MiRNAs are 21-24 nucleotides which have different levels of expression between tumors and normal tissues. In this study, we have analyzed expression level of miR-520d in three different groups of breast cancer.Methods: Fifty nine samples were divided into different groups according to their immunohistochemistry (IHC) classification: estrogen receptor (ER) positive and/or progesterone receptor (PR) positive group (as group I); human epidermal growth factor receptor 2 (HER2) positive group (as group II); and Triple negative group (as group III). After small RNA extraction from tissues, cDNAs were synthesized and Real time RTPCR carried out using DNA binding dye. Expression levels were analyzed by LinRegPCR and REST software.Results: MiR-520d under- expressed in all of three different groups. The expression ratio in groups I ,II, and III were 0.193, 0.167, 0.21, respectively but only the result from group II was significant (P=0.017). According to the different clinic-pathological status of breast cancer, miR-520d under-expressed significantly not only in patients with metastatic lymph node (P=0.019) but also in patients which have cancer at stage III (P=0.036). conclusion: In this study, we found that miR-520d possibly acts as a tumor suppressor. It may be useful for diagnosis of tumor from normal tissue. In addition, miR-520d significantly under-expressed in HER-2 positive group of breast cancers. Therefore, it may be useful as an additional diagnostic test in this group of breast tumors along with other biomarkers.Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, et al. Clinical significance of miR-21 expression in breast cancer:SYBR- Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009;21(3):673-9.
Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16(3):481-8.
Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S. Clinical impli- cations for BRCA gene mutation in breast cancer. Mol Biol Rep 2012;39(3):3097-102.
Jacob S, Praz F. DNA mismatch repair defects: role in colorectal car- cinogenesis. Biochimie 2002;84(1):27-47.
Gelbfish GA, Davidson AL, Kopel S, Schreibman B, Gelbfish JS, De- genshein GA, et al. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg 1988; 207(1):75-9.
Arteaga CL. Trastuzumab, an appropriate first-line single-agent ther- apy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 2003;5(2):96-100.
Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biop- sies. Mol Cancer 2006;5:24.
Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113(6):673-6.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are mi- croRNA targets. Cell 2005;120(1):15-20.
Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapop- totic factor in human glioblastoma cells. Cancer Res 2005;65(14):6029- 33.
Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, et al. Expression analysis of MiR-21, MiR-205, and MiR- 342 in breast cancer in Iran. Asian Pac J Cancer Prev 2012; 13(3):873-7.
Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evalua- tion of HER-2/neuimmunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002;118(3):408-17.
Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, et al. Amplifica- tion efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 2009;37(6):e45.
Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30(9):e36.
Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Leme- tre C, et al. MicroRNA signatures predict oestrogen receptor, proges- terone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009;11(3):R27.
Lao K, Xu NL, Sun YA, Livak KJ, Straus NA. Real time PCR profil- ing of 330 human micro-RNAs. Biotechnol J 2007;2(1):33-5.
| Files | ||
| Issue | Vol 5 No 3 (2013) | |
| Section | Original Articles | |
| Keywords | ||
| Breast cancer miR-520d real time RT-PCR SYBR green I Dye | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
